Categories AlphaGraphs, U.S. Markets News

HUD data revision points to weaker housing sector in the US

The US Department of Housing and Urban Development announced preliminary December home sales data on Tuesday, after being delayed by the partial shutdown of the federal government that ended in the last part of January.

The report also cut down the previously reported November sales of 657,000 units, revising it to 599,000 units. This indicated that the housing market is still in a state of weakening.

On a seasonally adjusted basis, new home sales inched 3.7% higher to an annual rate of 621,000 units.

However, single-family home sales rose by only 1.5% in 2018, while new home sales slipped 2.4% from a year ago.

Spiking mortgage rates, higher costs of lumber, and labor shortage had made homes less affordable last year. And this HUD report also showed that homebuilding dropped in December.

With the reasons mentioned above still being prevalent, the Street expects a weaker housing market.

US Housing Data for Dec 2018 by HUD

On a non-adjusted basis, new privately-owned houses for sale at the end of December 2018 were 343,000 at an average sales price of $377,000 per unit, compared to 294,000 in December 2017 at an average sales price of $402,900 per unit.

These show a ground reality of the real estate sector. And the latest downward revision of November number carries a negative implication, which could affect the housing sector further.

 

Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top